AZ chief: Emerging markets are tougher than you think

AstraZeneca ($AZN) CEO David Brennan (photo) talks emerging markets, external collaborations and townhall meetings in a Q&A with Roger Crockett. And, extending the current prefence for bolt-on M&A, Brennan reminds us that he's "not a fan" of megamergers. Report

Suggested Articles

Six pharmaceutical execs are set to head to Washington next week for pricing hearings at the House Committee on Oversight and Reform. 

After sifting through the data, one analyst figures the latest Opdivo-Keytruda showdown in kidney cancer might come down to commercial execution.

Biogen is giving former chief finance officer Jeff Capello a multimillion-dollar cash payment plus other severance benefits.